New External Study Demonstrates Strong Correlation of TriPath Imaging's ProEx Br Biomarkers with Risk of Breast Cancer Recurrence
12th Dec 2005, 13:51 GMT
Results from an External Research Study Presented at San Antonio Breast Cancer Symposium
New External Study Demonstrates Strong Correlation of TriPath Imaging's ProEx Br Biomarkers with Risk of Breast Cancer Recurrence related news:
- New External Study Demonstrates Strong Correlation of TriPath Imaging’s ProEx(TM) Br Biomarkers with Risk of Breast Cancer RecurrenceResults from an External Research Study Presented at San Antonio Breast Cancer Symposium — mysan.de
- Study shows positive results for TriPath test — Latest news from The Business Journal of the Greater Triad Area
- Radiotherapy aids breast cancer survival - study — KeralaNext: International
- Radiotherapy aids breast cancer survival: study (Reuters) — Yahoo! News: Health News
- Radiotherapy aids breast cancer survival: study — Reuters: Health
- SABCS: Shorter Chemotherapy Regimen Plus Taxol Reduces Breast Cancer Recurrence — MedPage Today Hematology/Oncology
- Radiotherapy aids breast cancer survival — MSNBC.com: Health
- Genomic Health Announces Study Results Demonstrating Oncotype DX 's Ability to Quantify Risk for Local and Regional Breast Cancer Recurrence — Surgery News from StratCenter.com
- Women With Breast Cancer Risk Developing Other Cancers — VOA News: Health
- VOA Health Brief 5:1 Women With Breast Cancer Risk Developing Other Cancers — VOA News: United States
Latest news from FDA News News from StratCenter.com:
- North American Gets Cancer Treatment OK
- North American Scientific Announces FDA Clearance of its ClearPath HDR Breast Brachytherapy System
- Newly FDA Approved SmartLipo Laser Liposuction Available at the Intimate Rejuvenation and Innovative Surgery Center, Phoenix, AZ.
- ACT-AD Coalition Calls FDA's New Focus on Neurological Diseases a Positive 1st Step
- Ivax Diagnostics Delays Filing 3Q Report
- New Corporate Members and Leaders for C-Path's Predictive Safety Testing Consortium Announced
- Diagnosoft Receives FDA Approval for Cardiac MRI Quantitative Regional Function Software Based on the HARP Technology
- PAREXEL Consulting Expands Risk Mgmt Expertise, Appoints Former FDA Consumer Safety Officer Raymond T Oji as Senior Consultant
- Trubion Pharmaceuticals to Present at the Lazard Life Sciences Conference
- Critical Therapeutics Announces Efficacy Data for Controlled-Release Formulation of Zileuton Presented at ACAAI 2006 Annual Meeting